Almac invests in analytical capabilities with new spectroscopy instrumentation at Craigavon lab

Published: 17-Jan-2025

The £500k investment will bring Agilent's 6545XT AdvanceBio Q-TOF Mass Spectrometer and Malvern's Panalytical Empyrean X-Ray Powder Diffractometer to the lab

Almac Sciences has invested £500k into instrumentation for the spectroscopy laboratory at its Craigavon headquarters.

By investing into a novel mass spectrometer and a x-ray powder diffractometer, Almac will be better equipped to provide analytical services to clients in the UK and further afield. 

With this cash, the company has purchased Agilent's 6545XT AdvanceBio Q-TOF Mass Spectrometer and Malvern's Panalytical Empyrean X-Ray Powder Diffractometer, as well as nuclear magnetic resonance spectrometers.

This follows the company's £11m investment into its analytical services across the globe. 

These investments substantially increase the company’s capabilities in solving complex analytical challenges and provide additional security for urgent analyses, additional processing capabilities and superior data integrity controls to ensure increasing regulatory compliance needs are met.

Within the dedicated facility, equipped with advanced LC-MS, GC-MS, ICP-MS, XRPD and NMR instrumentation, clients can benefit from a range of spectrometry services, including the quantitiation of:

  • Genetoxic impurities
  • Trace elemental analysis 
  • Isotopic purity determinations 
  • Structure elucidation
  • Crystalline phases

Companies will also have access to peptide, protein and glycoprotein and antibody analysis services, as well as polymorph screening, confirmation and quantitiation and confirmation.

Dr John Malone, Associate Director of Spectroscopy, Almac Sciences said: “The continued investment and growth in our spectroscopy laboratories underlines Almac’s commitment to providing the best analytical facilities for its customers, and seamlessly meeting their needs.  We are delighted to offer our clients cutting- edge technology that supports their product safety imperative and accelerates the drug development cycle.”

Dr Darren Thomas, Vice President of Analytical Operations commented: “As we continue to enhance our analytical capabilities, our commitment to excellence remains unwavering. This substantial investment in cutting-edge technology emphasises our dedication to offering comprehensive analytical solutions to clients around the world."

Relevant companies

You may also like